These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 18602642)

  • 1. Immunohistochemical application of an antibody specific for human CD1a to the diagnosis of canine mast cell tumour.
    Yhee JY; Hong SW; Yu CH; Doster AR; Blas-Machado U; Lyoo YS; Sur JH
    J Comp Pathol; 2008 Jul; 139(1):40-6. PubMed ID: 18602642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical and histochemical stains for differentiating canine cutaneous round cell tumors.
    Fernandez NJ; West KH; Jackson ML; Kidney BA
    Vet Pathol; 2005 Jul; 42(4):437-45. PubMed ID: 16006603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of serotonin and its 5-HT1A receptor in canine cutaneous mast cell tumours.
    Fröberg GK; Lindberg R; Ritter M; Nordlind K
    J Comp Pathol; 2009; 141(2-3):89-97. PubMed ID: 19446835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immunohistochemical study of vitamin D receptor expression in canine cutaneous mast cell tumours.
    Russell DS; Rassnick KM; Erb HN; Vaughan MM; McDonough SP
    J Comp Pathol; 2010; 143(2-3):223-6. PubMed ID: 20334872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of intratumoral vessel density in cutaneous mast cell tumors of the dog.
    Preziosi R; Sarli G; Paltrinieri M
    J Comp Pathol; 2004; 130(2-3):143-51. PubMed ID: 15003472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
    Kiupel M; Webster JD; Miller RA; Kaneene JB
    J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of immunohistochemical expression of BAX in formulating a prognosis for canine cutaneous mast cell tumours.
    Strefezzi Rde F; Kleeb SR; Xavier JG; Fukumasu H; Catão-Dias JL
    J Comp Pathol; 2012 May; 146(4):314-9. PubMed ID: 21899858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis.
    Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F
    Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between May-Grünwald-Giemsa and rapid cytological stains in fine-needle aspirates of canine mast cell tumour: Diagnostic and prognostic implications.
    Sabattini S; Renzi A; Marconato L; Militerno G; Agnoli C; Barbiero L; Rigillo A; Capitani O; Tinto D; Bettini G
    Vet Comp Oncol; 2018 Dec; 16(4):511-517. PubMed ID: 29961972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E-cadherin in canine mast cell tumors: decreased expression and altered subcellular localization in Grade 3 tumors.
    Mackowiak II; Gentile LB; Chaible LM; Nagamine MK; Guerra JM; Mota EF; Matera JM; Mennecier G; Sanches DS; Dagli ML
    Vet J; 2012 Dec; 194(3):405-11. PubMed ID: 22766308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of cyclooxygenase-2 expression in canine mast cell tumours.
    Prada J; Queiroga FL; Gregório H; Pires I
    J Comp Pathol; 2012 Jul; 147(1):31-6. PubMed ID: 22079567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours.
    Meyer A; Gruber AD; Klopfleisch R
    J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical evaluation of prostaglandin E2 and vascular endothelial growth factor in canine cutaneous mast cell tumours.
    Amorim RL; Pinczowski P; Neto RT; Rahal SC
    Vet Comp Oncol; 2010 Mar; 8(1):23-7. PubMed ID: 20230578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.
    Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V
    Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy.
    Ranieri G; Passantino L; Patruno R; Passantino G; Jirillo F; Catino A; Mattioli V; Gadaleta C; Ribatti D
    Oncol Rep; 2003; 10(5):1189-93. PubMed ID: 12883679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of p27 and p21 in canine cutaneous mast cell tumors and histiocytomas.
    Wu H; Hayashi T; Inoue M
    Vet Pathol; 2004 May; 41(3):296-9. PubMed ID: 15133184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous mast cell tumor with epitheliotropism in 3 dogs.
    Oliveira FN; Elliott JW; Lewis BC; Mathews GG; Brown RM; Treadway CM; Langohr IM
    Vet Pathol; 2013 Mar; 50(2):234-7. PubMed ID: 22700850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of KIT receptor in feline cutaneous mast cell tumors.
    Rodriguez-Cariño C; Fondevila D; Segalés J; Rabanal RM
    Vet Pathol; 2009 Sep; 46(5):878-83. PubMed ID: 19429979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment.
    Welle MM; Bley CR; Howard J; Rüfenacht S
    Vet Dermatol; 2008 Dec; 19(6):321-39. PubMed ID: 18980632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours.
    Tamlin VS; Kessell AE; Mccoy RJ; Dobson EC; Smith TS; Hebart M; Brown L; Mitrovic D; Peaston AE
    Aust Vet J; 2017 Oct; 95(10):386-391. PubMed ID: 28948627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.